RHÖN-KLINIKUM Aktiengesellschaft/€RHK

1D1W1MYTD1Y5YMAX

About RHÖN-KLINIKUM Aktiengesellschaft

RHÖN-KLINIKUM AG is a German healthcare provider operating five hospital sites: Campus Bad Neustadt, Klinikum Frankfurt (Oder), Universitätsklinikum Gießen, Universitätsklinikum Marburg (UKGM), and Zentralklinik Bad Berka. The company offers inpatient and outpatient medical services, treating approximately 913,000 patients annually. Headquartered in Bad Neustadt a. d. Saale, Germany, RHÖN-KLINIKUM AG employs over 18,700 individuals. In 2020, Asklepios Kliniken GmbH & Co. KGaA acquired a majority stake in RHÖN-KLINIKUM AG, leading to a strategic partnership while maintaining RHÖN-KLINIKUM AG's independence within the Asklepios group. The company focuses on cross-sector healthcare delivery, digital transformation, and sustainability initiatives, including plans to achieve CO₂-neutrality in Scope 1 and Scope 2 emissions by 2040.
Ticker
€RHK
Sector
Health
Primary listing
XETRA
Employees
19,120
Headquarters
Bad Neustadt an der Saale, Germany
Website
www.rhoen-klinikum-ag.com

RHK Metrics

BasicAdvanced
€971M
22.82
€0.63
-
€0.20
1.39%

Bulls say / Bears say

H1 FY26 net income climbed 53.1% to EUR 22.5 million, up from EUR 14.7 million a year earlier, underscoring robust profitability momentum despite sector challenges. (Reuters)

Q1 FY26 consolidated revenue rose to EUR 436.1 million from EUR 414.7 million in Q1 2025, reflecting steady top-line growth in a reform-impacted environment. (Reuters)

Q1 FY26 patient volumes grew 7.4% year-over-year and the integration of Ortho Centrum Saale MVZ GmbH bolstered the outpatient care segment, supporting diversification and scale. (Reuters)

Company warned fiscal 2026 outlook is subject to significant uncertainty due to the Hospital Reform Adjustment Act and Statutory Health Insurance Contribution Rate Stabilisation Act, which may exacerbate short-term financial pressures on operations. (Reuters)

Shares trade at a forward P/E of 19x, above the healthcare peer group average of 17x, suggesting limited valuation upside if regulatory or economic headwinds intensify. (Reuters)

Full-year 2026 guidance of €1.7 billion ±5% revenue and €110–125 million EBITDA implies a narrow growth corridor, offering little buffer against execution or reform-related risks. (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2026.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.